Cullinan Oncology Inc (CGEM) |
|
Price: $10.0500
$0.49
5.126%
|
Day's High:
| $10.91
| Week Perf:
| 9.96 %
|
Day's Low: |
$ 9.50 |
30 Day Perf: |
3.93 % |
Volume (M): |
2,062 |
52 Wk High: |
$ 15.89 |
Volume (M$): |
$ 20,718 |
52 Wk Avg: |
$11.87 |
Open: |
$9.54 |
52 Wk Low: |
$7.78 |
|
|
Market Capitalization (Millions $) |
409 |
Shares
Outstanding (Millions) |
41 |
Employees |
2 |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
64 |
Cash Flow (TTM) (Millions $) |
46 |
Capital Exp. (TTM) (Millions $) |
1 |
Cullinan Oncology Inc
Consolidated Gems, Inc., formerly Electrum International, Inc. is a Delaware corporation
that was originally incorporated in Florida as We Sell for U Corp. (“We
Sell for U”) on November 12, 2007. The principal stockholder of Consolidated
Gems is Power Developments Pty Ltd., an Australian corporation (“Power”),
an entity majority owned by the Company’s president, which owned 82.85%
of Consolidated Gems as of December 31, 2016.
Company Address: One Main Street Cambridge 2142
Company Phone Number: 410-4650 Stock Exchange / Ticker: NASDAQ CGEM
CGEM is expected to report next financial results on August 09, 2023. |
|
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Fgi Industries Ltd
Fgi Industries Ltd, a Renewable Energy Services and Equipment company, recently declared disappointing financial results for the first quarter of 2023. The company's Revenue fell by a significant -37.666% to $27.16 million, and they posted a net loss per share to $-0.03, in proportion to $0.05. This is a significant decline compared to their preceding financial reporting period, where Income per Share was $0.07 per share, and Revenue deteriorated by -14.558% from $31.79 million. Furthermore, the company's net shortfall was $-0.303 million this quarter, rather than the zero gain they recorded for the same financial reporting period a year before. Such statistics raise several questions regarding the future of Fgi Industries Ltd. First and foremost, the decline in Revenue is a significant red flag. This statistic alone can be enough to set alarm bells ringing around shareholders and investors alike. As the company is involved in Renewable Energy Services and Equipment, it is essential to determine why Revenue has fallen and possibly predict whether this trend will continue.
|
Cullinan Oncology Inc
Cullinan Oncology Inc is a biotechnology company focused on developing targeted cancer therapies. With headquarters in Cambridge, Massachusetts, USA, the company was founded in 2017 and went public in 2020. Cullinan Oncology Inc operates in the Renewable Energy Services and Equipment industry, offering innovative treatments for cancer patients. The company is known for its innovative technologies in the field of oncology and has achieved great milestones in the industry. Recently, the Renewable Energy Services and Equipment industry consultants have begun scrutinizing the company's first quarter of 2023 performance. Presently, these consultants have monitored an operating shortfall of $-62.756 million from the CGEM, which hasn't recorded any revenue so far for the respective January to March 31, 2023, quarter. The consultants advise to frame the financial first quarter of 2023 outcome, at the prevailing instance of the business. Currently, it is easy to correlate the operating shortfall of the first quarter of 2022, which came in at $-32.657 million. On the quest to prompt the lucrative revenue sources, entities frequently undergo uncommonly choppy stints. May be one of these, is the financial span ending March 31, 2023, where the deficit has extended to $-58.141 million. In the coming days, Cullinan Oncology Inc is expected to report its next financial results on May 15, 2023. The company's income per employee fell on a trailing twelve-month basis to $31,973,000, but the productivity of Cullinan Oncology Inc's 2 employees remained above the company average. This is a reflection of the company's continued commitment to excellence and innovation. The Renewable Energy Services and Equipment industry has seen Cullinan Oncology Inc achieve the highest income per employee. Meanwhile, Cullinan Oncology Inc's overall ranking has deteriorated compared to the fourth quarter of 2022, from $31,973,000. This may be attributed to the unforeseeable challenges in the industry or the choppy period experienced by entities in the quest to prompt the lucrative revenue sources. However, considering the milestones achieved by Cullinan Oncology Inc as a biotechnology company, such challenges may be surmounted shortly.
|
Babcock And Wilcox Enterprises Inc
As a financial journalist, it is my job to interpret the financial results of the companies and present them to the public in a concise and informative manner. In this article, I will be discussing the financial results of Babcock and Wilcox Enterprises Inc for the fiscal year ending in the first quarter of 2023. The company has recorded a cumulative net loss of $-30 million during this 12-month period, resulting in a negative return on investment of -5.22%. This indicates that the company is not currently profitable and has not been able to generate a positive return for its investors.
|
Omega Flex Inc
As investors, we are often bombarded with seemingly conflicting financial news and data. On the one hand, we hear about companies improving their net earnings and increasing their profit margins. On the other hand, we hear about diminishing revenue and decreased income per share. The recent financial results of Omega Flex Inc, a manufacturer of flexible metal hose products, seem to fall into this category of information. In the financial time-frame closing March 31, 2023, Omega Flex Inc reported an improvement in earnings per share, with income per share increasing by 5.56% to $0.57 per share. However, revenue saw a decline of -4.173% to $29.99 million, year on year. The results from the previous quarter also show a decrease in revenue of -2.693% and a decrease in income per share of -6.92%. As investors, it is important to pay attention to both the positive and negative aspects of the company's financial performance.
|
The Aes Corporation
|
Per Share |
Current |
Earnings (TTM) |
1.3 $ |
Revenues (TTM) |
-
|
Cash Flow (TTM) |
1.13 $ |
Cash |
9.6 $
|
Book Value |
11.94 $
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
1.3 $
|
Revenues (TTM) |
- |
Cash Flow (TTM) |
1.13 $ |
Cash |
9.6 $
|
Book Value |
11.94 $ |
Dividend (TTM) |
0 $ |
|
|
|
|